Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Anant Mohan, Pawan Tiwari, Tejas Menon Suri, et al.
Journal of Infection and Chemotherapy (2021) Vol. 27, Iss. 12, pp. 1743-1749
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Andrew Bryant, Theresa A Lawrie, Therese Dowswell, et al.
American Journal of Therapeutics (2021) Vol. 28, Iss. 4, pp. e434-e460
Open Access | Times Cited: 227
Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 154
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Ivermectin for preventing and treating COVID-19
Maria Popp, Miriam Stegemann, Maria‐Inti Metzendorf, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 89
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
Elisa Souza Vaz, Sandra V. Vassiliades, Jeanine Giarolla, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 6, pp. 723-751
Open Access | Times Cited: 16
Ivermectin as a Treatment Modality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Up-To-Date RCTs
Raghava Kalyan Maddukuri, Madhavi Latha Desimalla, Reshma Banavathu, et al.
Indian Journal of Community Medicine (2025) Vol. 50, Iss. 1, pp. 9-19
Open Access
Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis
Jiawen Deng, Fangwen Zhou, Saif Ali, et al.
QJM (2021) Vol. 114, Iss. 10, pp. 721-732
Open Access | Times Cited: 33
Drug safety of frequently used drugs and substances for self-medication in COVID-19
Daniela Baracaldo-Santamaría, Santiago Pabón-Londoño, Luis Carlos Rojas-Rodríguez
Therapeutic Advances in Drug Safety (2022) Vol. 13
Open Access | Times Cited: 23
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
Mohsen Nabi‐Afjadi, Fatemeh Mohebi, Hamidreza Zalpoor, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 1, pp. 21-35
Open Access | Times Cited: 14
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Zhilong Song, Senyuan Shi, Yongli Zhang
Heliyon (2024) Vol. 10, Iss. 6, pp. e27647-e27647
Open Access | Times Cited: 4
Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients
Arman Shafiee, Mohammad Mobin Teymouri Athar, Omid Kohandel Gargari, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results
Ariel Izcovich, Sasha Peiris, Martín Ragusa, et al.
Journal of Clinical Epidemiology (2021) Vol. 144, pp. 43-55
Open Access | Times Cited: 24
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view
Farshad M. Shirazi, Roya Mirzaei, Samaneh Nakhaee, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 17
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Qinglin Cheng, Chen Jun-fang, Qingjun Jia, et al.
Aging (2021) Vol. 13, Iss. 18, pp. 21866-21902
Open Access | Times Cited: 22
Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells
Nilima Dinesh Kumar, Bram M. ter Ellen, Ellen M. Bouma, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 66, Iss. 1
Open Access | Times Cited: 22
Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce
Heath White, Steve McDonald, Bridget E. Barber, et al.
The Medical Journal of Australia (2022) Vol. 217, Iss. 7, pp. 368-378
Open Access | Times Cited: 14
Identification and Development of Therapeutics for COVID-19
Halie M. Rando, Nils Wellhausen, Soumita Ghosh, et al.
mSystems (2021) Vol. 6, Iss. 6
Open Access | Times Cited: 19
Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials
Mohammad Sadegh Rezai, Fatemeh Ahangarkani, Andrew Hill, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 12
Is Ivermectin Effective in Treating COVID-19?
Shuangshuang Yang, Shan Shen, Ning Hou
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11
Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants
Océane Delandre, Mathieu Gendrot, Priscilla Jardot, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 4, pp. 445-445
Open Access | Times Cited: 10
A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality
Thairu Yunusa, Olawale Babalola, A. A. Ajayi, et al.
Journal of Pharmaceutical Research International (2022), pp. 1-19
Open Access | Times Cited: 9
Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial
Ananda Wijewickrema, Hasini Banneheke, A. Pathmeswaran, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Steven G. Rothrock, Kurt Weber, Philip Giordano, et al.
American Journal of Therapeutics (2022) Vol. 29, Iss. 2, pp. e237-e244
Open Access | Times Cited: 7
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial
Carmen de la Rocha, Marco A. Cid-López, Blanca I. Venegas-López, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top